



December 20, 2016

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2010-019856-30/ Novartis Protocol ID CLDE225B2307

*A randomized, double-blind, vehicle-controlled, multicenter trial of topically administered LDE225 cream [0.75% bid] to evaluate clearance of Basal Cell Carcinoma in adult patients with Nevoid Basal Cell Carcinoma Syndrome*

Trial CLDE225B2307 was cancelled with no patient enrollment and as such, no results will be reported.